Lantheus (LNTH) Expected to Announce Earnings on Thursday

Lantheus (NASDAQ:LNTH) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Lantheus to post earnings of $1.57 per share and revenue of $376.61 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Lantheus Trading Down 2.4 %

Shares of NASDAQ:LNTH opened at $81.39 on Thursday. Lantheus has a 12-month low of $56.06 and a 12-month high of $126.89. The business’s fifty day simple moving average is $90.82 and its 200-day simple moving average is $97.32. The company has a market capitalization of $5.66 billion, a PE ratio of 13.54 and a beta of 0.44.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on LNTH shares. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.